It was an extremely busy week in the biotech sector, with several companies making important presentations at the J.P. Morgan ...

Retinal Biologics Industry. The retinal biologics market experienced significant growth in 2021, with total revenue reaching ...

Ocugen (OCGN) announced that the first patient has been dosed in the OCU200 Phase 1 clinical trial for diabetic macular edema, DME. “OCU200 has ...

Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and ...

Bell Potter has reaffirmed its speculative buy rating and $1.30 price target on the ASX stock. Based on its current share ...

XOMA Royalty Corporation's portfolio includes riskier assets, impacting its stability. Find out why XOMA stock’s high-risk ...

Patients with a foveal bulge had significantly enhanced visual acuity if they also had resolved diabetic macular edema (DME) ...

After Regeneron Chief Scientific Officer George Yancopoulos, M.D., Ph.D., spent more than 25 minutes waxing about the company ...

Further, all patients in the AXPAXLI arm who presented with non-center-involved diabetic macular edema (non-CI-DME) at baseline (N=8) had improvement in their DME based on Optical Coherence Tomography ...

Further, all patients in the AXPAXLI arm who presented with non-center-involved diabetic macular edema (non-CI-DME) at baseline (N=8) had improvement in their DME based on Optical Coherence Tomography ...

D Molecular Therapeutics (NASDAQ:FDMT) and the U.S. FDA have reached agreement on a phase 3 trial design for diabetic macular ...